

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Sequent Scientific Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Sequent Scientific Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure 1 to the auditor's review report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



SRBC & CO LLP

Chartered Accountants

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
- Fourteen subsidiaries, whose unaudited interim financial results include total revenues of Rs. 26,062 lakhs and Rs 75,886 lakhs, total net profit/(loss) after tax of Rs. 898 lakhs and Rs. (216) lakhs, total comprehensive income/(loss) of Rs. 2,741 lakhs and Rs. (1,053) lakhs, for the quarter ended December 31, 2022 and the period ended on that date respectively, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:
- Three subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs 226 lakhs and Rs 738 lakhs, total net loss after tax of Rs. 17 lakhs and Rs. 62 lakhs, total comprehensive loss of Rs. 88 lakhs and Rs. 180 lakhs, for the quarter ended December 31, 2022 and the period ended on that date respectively and for the period from April 01, 2022 to December 31, 2022.


The unaudited interim financial results and other unaudited financial information of these subsidiaries have not been audited/reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For SRBC & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003



per Anil Jobanputra

Partner

Membership No.: 110759

UDIN: 23110759BGVZQX1959

Place: Thane

Date: February 14, 2023



SRBC & CO LLP

Chartered Accountants

Annexure 1 to Auditor's review report

Name of the Holding Company

1. Sequent Scientific Limited

Including its following wholly-owned subsidiaries:

2. Alivira Animal Health Limited, India
3. Sequent Research Limited

Including its following subsidiary:

4. Alivira Animal Health Limited, Ireland

Including its following subsidiaries and sub subsidiaries:

5. Comercial Vila Veterinaria De Lleida S.L.
6. Laboratorios Karizoo, S.A.
7. Phytotherapic Solutions S.L.
8. Vila Viña Participacions, S.L.
9. Alivira Saude Animal Ltda
10. Alivira Saude Animal Brasil Participacoes Ltda
11. Evanvet Distribuidora De Produtos Veterinarios Ltda
12. Provet Veteriner Ürünleri San. Ve Tic. A. Ş.
13. Topkim Topkapi İlaç premiks Sanayi Ve Ticaret A.Ş.
14. Laboratorios Karizoo, S.A. de C.V. (Mexico)
15. Alivira Animal Health UK Limited
16. Alivira France S.A.S
17. Alivira Italia S.R.L.
18. Alivira Animal Health USA LLC
19. Fendigo BV
20. Nourrie Saude e Nutricao Animal Ltda (amalgamated with Alivira Saude Animal Ltda on 1st July 2022)
21. N-Vet AB
22. Bremer Pharma GmbH
23. Fendigo SA



Sequent

SEQUENT SCIENTIFIC LIMITED

CIN: L99999MH1985PLC036685

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2022

(₹ in Lakhs)

Sr. No.	Particulars	3 months ended 31-Dec-2022	Preceding 3 months ended 30-Sep-2022	Corresponding 3 months ended in previous period 31-Dec-2021	Year to date for current period ended 31-Dec-2022	Corresponding year to date for previous period 31-Dec-2021	Previous year ended 31-Mar-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited Restated (Refer Note 6)
I	Revenue from operations	37,531.30	33,760.70	35,804.70	1,05,424.10	1,02,910.70	1,41,281.60
II	Other income	286.30	91.10	366.80	465.30	707.50	1,084.50
III	Total income (I+II)	37,817.60	33,851.80	36,171.50	1,05,889.40	1,03,618.20	1,42,366.10
IV	Expenses						
	(a) Cost of materials consumed	17,213.40	16,402.20	16,015.20	51,528.40	48,976.20	67,052.20
	(b) Purchases of stock-in-trade	2,909.90	3,215.80	4,272.70	9,735.90	13,074.90	17,188.90
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,619.70	170.70	463.70	(62.20)	(4,630.90)	(4,941.50)
	(d) Employee benefits expense	6,687.80	6,245.50	4,627.70	19,382.40	17,418.40	23,136.80
	(e) Finance costs	972.50	812.10	345.00	2,464.70	973.60	1,577.40
	(f) Depreciation and amortisation expenses (Refer note 6)	1,367.40	1,338.40	1,283.30	4,098.80	3,861.40	5,154.10
	(g) Acquisition related cost (Refer note 7b)	99.00	-	-	99.00	-	-
	(h) Other expenses	7,682.90	7,105.40	6,803.40	22,188.10	20,466.70	27,905.20
	(i) Net Monetary loss on Hyperinflation economy (Refer note 4)	284.90	334.10	-	1,020.20	-	-
	Total expenses (IV)	38,837.50	35,624.20	33,811.00	1,10,455.30	1,00,140.30	1,37,073.10
V	Profit / (loss) before tax and exceptional items (III-IV)	(1,019.90)	(1,772.40)	2,360.50	(4,565.90)	3,477.90	5,293.00
VI	Exceptional item (Refer note 5)	-	-	-	(319.80)	-	-
VII	Profit / (loss) before tax (V-VI)	(1,019.90)	(1,772.40)	2,360.50	(4,885.70)	3,477.90	5,293.00
VIII	Tax expense / (credit)						
	(a) Current tax	96.30	418.00	624.30	509.60	1,525.80	2,572.80
	(b) Deferred tax (Refer Note 6)	(2.00)	(1,711.40)	(179.60)	(2,270.10)	(266.90)	(553.20)
	(c) Adjustment of tax pertaining to earlier period	(136.50)	(34.90)	60.20	(171.40)	(1,283.40)	(1,203.00)
	Total tax expense / (credit)	(42.20)	(1,328.30)	504.90	(1,931.90)	(24.50)	816.60
IX	Profit / (loss) after tax (VII-VIII)	(977.70)	(444.10)	1,855.60	(2,953.80)	3,502.40	4,476.40
X	Other comprehensive income / (expense)						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurement gain / (loss) on defined benefits plans	-	(19.60)	7.40	(9.10)	15.00	1.40
	(b) Fair value gain / (loss) from investment in equity instruments	1.80	298.00	(3,198.40)	(1,424.60)	(2,055.00)	(4,006.70)
	(c) Income tax relating to items that will not be reclassified to profit or loss	96.90	(153.20)	-	(59.20)	-	(1.60)
	(d) Deferred tax relating to items that will not be reclassified to profit or loss	(95.90)	168.70	370.00	274.40	234.60	451.20
	Items that will be reclassified to profit or loss						
	(a) Exchange differences on translation of foreign operations	1,423.40	(1,300.80)	(4,017.40)	(859.10)	(4,941.10)	(6,058.00)
	(b) Exchange differences on net investment in foreign operations	956.20	(574.00)	(1,977.30)	(336.50)	(1,911.80)	(1,252.30)
	Total other comprehensive income / (expense) (net of tax)	2,382.40	(1,580.90)	(8,815.70)	(2,414.10)	(8,658.30)	(10,866.00)
XI	Total comprehensive income / (expense), net of tax (IX+X)	1,404.70	(2,025.00)	(6,960.10)	(5,367.90)	(5,155.90)	(6,389.60)
	Profit / (loss) attributable to:						
	- Owners of the Company	(886.90)	(375.00)	1,711.60	(2,758.50)	3,228.90	4,095.50
	- Non-controlling interest	(90.80)	(69.10)	144.00	(195.30)	273.50	380.90
	Other comprehensive income / (expense) attributable to:						
	- Owners of the Company	2,169.40	(1,533.50)	(8,753.20)	(2,538.60)	(8,603.80)	(10,837.50)
	- Non-controlling interest	213.00	(47.40)	(62.50)	124.50	(54.50)	(28.50)
	Total comprehensive income / (expense) attributable to:						
	- Owners of the Company	1,282.50	(1,908.50)	(7,041.60)	(5,297.10)	(5,374.90)	(6,742.00)
	- Non-controlling interest	122.20	(116.50)	81.50	(70.80)	219.00	352.40
XII	Equity share capital (face value of ₹ 2 each)	4,988.70	4,988.70	4,967.40	4,988.70	4,967.40	4,967.40
XIII	Other equity						64,242.40
XIV	Earnings per equity share: (face value of ₹ 2 each) (not annualised)						
	(1) Basic (in ₹)	(0.36)	(0.15)	0.69	(1.11)	1.31	1.65
	(2) Diluted (in ₹)	(0.36)	(0.15)	0.68	(1.11)	1.29	1.63
	See accompanying notes to the unaudited consolidated financial results						



Sequent

SEQUENT SCIENTIFIC LIMITED
CIN: L99999MH1985PLC036685

- Notes:**
- 1 The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14 February 2023
- 2 As the Board of Directors monitors the business activity as a single segment viz Pharmaceuticals the financial results are reflective of the disclosure requirements of Ind AS 108 - Operating Segments
3. Information on Standalone Results: (₹ in Lakhs)

Particulars	3 months ended 31-Dec-2022	Preceding 3 months ended 30-Sep-2022	Corresponding 3 months ended in previous period 31-Dec-2021	Year to date for current period ended 31-Dec-2022	Corresponding year to date for previous period 31-Dec-2021	Previous year ended 31-Mar-2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	5,699.90	5,423.10	5,919.10	17,609.00	15,595.30	21,962.60
Profit / (loss) before tax	(399.40)	(567.70)	551.60	(851.60)	765.30	1,569.00
Profit / (loss) after tax	(122.51)	(405.00)	447.26	(443.50)	815.06	1,479.90
Total comprehensive income / (expense), (net of tax)	(120.67)	(94.58)	(2,379.32)	(1,651.40)	(1,001.58)	(2,051.80)

4 The Group has applied IND AS 29 'Accounting for Hyperinflationary economies' on Turkish subsidiaries, since the Turkish Lira is a functional currency of these subsidiaries in Turkey which is a hyperinflationary economy. In preparing the consolidated financial results for the quarter and nine months ended 31 December 2022, the non-monetary assets (includes goodwill, property, plant and equipment, etc), liabilities, owner's equity and statement of profit and loss of the aforesaid subsidiaries have been restated to the measuring unit current as on the reporting date by applying general price index of the Turkish economy. Considering that the presentation currency of consolidated financial results is INR, the restatement of comparative figures in consolidated financial results is not required. The impact of said restatements till 31 March 2022 of aforesaid subsidiaries has been considered in the opening retained earnings as at 01 April 2022.

5 Exceptional Item: represents estimated loss of book value of assets (Property, Plant and Equipment and Inventory) amounting to ₹ 319.80 lakhs due to an incident of fire at Company's wholly owned subsidiary Alivira Animal Health Limited's (Alivira) API facility in Visakhapatnam on 07 May 2022. The manufacturing activities were temporarily disrupted and is currently operating under normalcy. Alivira has submitted the insurance claim and the same is under process with Insurance Company.

6 The Group, through its wholly owned subsidiary Alivira Saúde Animal Ltda, Brazil (formerly known as Evance Saude Animal Health Ltda) had acquired 100% equity in Nourme Saude e Nutrição Animal Ltda (Nourme) on 28 February 2022 vide "Quota Purchased and Sale and Other Covenant" agreement, for a consideration of ₹ 3,937.80 lakhs (BRL 270 lakhs). Consequently, the Group has consolidated the financial statement of the said Company with effect from 28 February 2022. As the measurement period was on going, the group had provisionally recognised assets and liabilities. The Purchase Price Allocation (PPA) has been finalised in the current period and consequently the financial results for the comparative periods are restated in accordance with Ind AS 103 Business Combination" as under.

Particulars	(₹ in Lakhs)	
	Final PPA	Provisional PPA
Goodwill	1,937.72	2,352.90
Intangible assets	2,583.43	1,338.90
Deferred tax liability	(912.70)	-
Net assets	329.35	246.00
Total	3,937.80	3,937.80

Accordingly the aforesaid impact in the Statement of Profit & Loss for the year ended 31 March 2022 have been restated as below
Financial Results for the year ended 31 March 2022

Particulars	Restated as on 31 March 2022	Impact	Reported as on 31 March 2022
Depreciation and amortisation expenses	5,154.10	45.60	5,108.50
Profit / (loss) before tax	5,293.00	(45.60)	5,338.60
Profit / (loss) after tax	4,476.40	(29.60)	4,506.00

During the current period (effective 01 July 2022), Nourme has been amalgamated with Alivira Saúde Animal Ltda, Brazil (wholly-owned subsidiary of the Company) and accordingly amortisation of intangible assets and goodwill generated on the amalgamation will be admissible expenditure under local Income tax laws. Consequently, deferred tax income/ asset amounting to ₹ 1,203.10 lakhs has been recognized during the period.

7a The Board of Directors, at its meeting held on November 07, 2022, have approved the acquisition of 100% equity shares in Tineta Pharma Private Limited (TPPL) (a Company incorporated in India and in the business of animal health and therapeutic formulations) for a total consideration of ₹ 21,800 lakhs comprising a cash component of ₹ 15,300 lakhs, the balance of ₹ 6,500 lakhs being discharged through equity shares in the Company, to be allotted on preferential basis to the shareholders in TPPL as per a share swap ratio determined by a registered valuer. Pursuant to the Board approval, the Company has entered into a Share Purchase Agreement (SPA) with the shareholders of TPPL on the aforesaid date. Shareholders approval for allotment of shares on preferential basis has been accorded through a postal ballot on December 10, 2022. The process of completing the transaction closing pre-requisites is underway.

7b Acquisition related cost represents cost incurred towards proposed acquisition of TPPL (refer note 7a above) comprising of stamp duty on shares purchase agreement, legal and professional fees and related expenses.

8 The previous period figures have been regrouped / reclassified wherever necessary to conform to current period's presentation.

For Sequent Scientific Limited



Rajaram Narayanan
Managing Director

Thane, 14 February 2023

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Sequent Scientific Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Sequent Scientific Limited (the "Company") for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003



per Anil Jobanputra

Partner

Membership No.: 110759



UDIN: 23110759BGVZQW3917

Place: Thane

Date: February 14, 2023

Sequent

SEQUENT SCIENTIFIC LIMITED

CIN: L99999MH1985PLC036685

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2022

(₹ in lakhs)

Sr. No.	Particulars	3 months ended 31-Dec-2022	Preceding 3 months ended 30-Sep-2022	Corresponding 3 months ended in previous period 31-Dec-2021	Year to date figure for the current period ended 31-Dec-2022	Corresponding year to date for previous period ended 31-Dec-2021	Previous year ended 31- Mar-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	5,699.90	5,423.10	5,919.10	17,609.00	15,595.30	21,962.60
II	Other income	762.30	672.60	569.70	2,022.90	2,187.10	2,764.30
III	Total income (I+II)	6,462.20	6,095.70	6,488.80	19,631.90	17,782.40	24,726.90
IV	Expenses						
	(a) Cost of materials consumed	3,274.70	2,373.60	2,080.17	9,674.20	8,358.57	12,400.68
	(b) Purchases of stock-in-trade	64.60	-	125.43	223.90	217.33	438.22
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	349.80	958.90	1,410.00	910.50	(1,087.10)	(1,973.30)
	(d) Conversion and processing charges	698.20	658.30	754.60	2,054.40	2,981.40	3,757.50
	(e) Employee benefits expenses	922.00	922.30	126.30	2,796.50	2,288.80	2,738.20
	(f) Finance costs	71.70	57.50	55.60	164.60	100.20	161.00
	(g) Depreciation and amortisation expenses	215.40	224.90	240.40	678.40	725.20	959.30
	(h) Acquisition related cost (refer note 3b)	99.00	-	-	99.00	-	-
	(i) Other expenses	1,166.20	1,467.90	1,144.70	3,882.00	3,432.70	4,676.30
	Total expenses (IV)	6,861.60	6,663.40	5,937.20	20,483.50	17,017.10	23,157.90
V	Profit / (loss) before tax (III-IV)	(399.40)	(567.70)	551.60	(851.60)	765.30	1,569.00
VI	Tax expense / (credit)						
	(a) Current tax	0.01	(19.01)	133.44	2.00	133.44	251.20
	(b) Deferred tax	(139.80)	(143.69)	(29.10)	(273.00)	21.60	52.00
	(c) Adjustment of income tax relating to earlier periods	(137.10)	-	-	(137.10)	(204.80)	(214.10)
	Total tax expense / (credit)	(276.89)	(162.70)	104.34	(408.10)	(49.76)	89.10
VII	Profit / (loss) after tax (V-VI)	(122.51)	(405.00)	447.26	(443.50)	815.06	1,479.90
VIII	Other comprehensive income / (expense)						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurements gain / (loss) on defined benefits plans	-	3.90	(1.20)	6.50	(2.30)	10.50
	(b) Fair value gain / (loss) from investment in equity instruments	1.80	298.00	(3,198.40)	(1,424.50)	(2,055.00)	(4,006.70)
	(c) Income tax relating to items that will not be reclassified to profit or loss	95.91	(160.11)	-	(64.20)	-	-
	(d) Deferred tax relating to items that will not be reclassified to profit or loss	(95.87)	168.63	373.02	274.40	240.66	464.50
	Total other comprehensive income / (expense) (net of tax)	1.84	310.42	(2,826.58)	(1,207.90)	(1,816.64)	(3,531.70)
IX	Total comprehensive income / (expense), net of tax (VII+VIII)	(120.67)	(94.58)	(2,379.32)	(1,651.40)	(1,001.58)	(2,051.80)
X	Equity share capital (face value of ₹ 2 each)	4,988.70	4,988.70	4,967.40	4,988.70	4,967.40	4,967.40
XI	Other equity	-	-	-	-	-	99,141.41
XII	Earnings per equity share: (face value of ₹ 2 each) (not annualised)						
	(1) Basic (in ₹)	(0.05)	(0.16)	0.18	(0.18)	0.33	0.60
	(2) Diluted (in ₹)	(0.05)	(0.16)	0.18	(0.18)	0.32	0.59
	See accompanying notes to unaudited standalone financial results						



Sequent

SEQUENT SCIENTIFIC LIMITED
CIN L99999MH1985PLC036685

Notes:

- 1 The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14 February 2023
- 2 As the Board of Directors monitors the business activity as a single segment viz Pharmaceuticals the financial results are reflective of the disclosure requirements of Ind AS 108 - Operating Segments
- 3a The Board of Directors, at its meeting held on November 07, 2022, have approved the acquisition of 100% equity shares in Tineta Pharma Private Limited (TPPL) (a Company incorporated in India and in the business of animal health and therapeutic formulations) for a total consideration of ₹ 21 800 lakhs comprising a cash component of ₹ 15,300 lakhs, the balance of ₹ 6,500 lakhs being discharged through equity shares in the Company, to be allotted on preferential basis to the shareholders in TPPL as per a share swap ratio determined by a registered valuer Pursuant to the Board approval, the Company has entered into a Share Purchase Agreement (SPA) with the shareholders of TPPL on the aforesaid date Shareholders approval for allotment of shares on preferential basis has been accorded through a postal ballot on December 10 2022 The process of completing the transaction closing pre-requisites is underway
- 3b Acquisition related cost represents cost incurred towards proposed acquisition of TPPL (refer Note 3a above) comprising of stamp duty on shares purchase agreement, legal and professional fees and related expenses
- 4 The previous period figures have been regrouped/re-classified wherever necessary to conform to current period's presentation

Thane, 14 February 2023



For Sequent Scientific Limited

Rajaram Narayanan
Managing Director